Visit Sanpower About Us Our Commitment Our History Corporate Governance Our Science Partner With Us Newsroom Join Us Contact Us About Us Pioneering the future of immunotherapy Founded on the belief that immunotherapy made from a patient’s own cells will transform cancer treatment, Dendreon is fighting for patients by making the battle against cancer personal. By harnessing the power of the body’s immune system, we help extend the lives of patients battling cancer. Our flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. Since its approval in 2010, nearly 40,000 men with advanced prostate cancer have been prescribed PROVENGE. Today, we continue to push our research forward so that we may help even more patients fight cancer with personalized immunotherapy. Our Mission Making the battle against cancer personal through immunotherapy treatments that extend lives. Our Commitment In the fight against cancer, our patients aren’t giving up, and neither are we. We aim to extend life without reducing quality of life. This commitment — to patients, families, and the physicians who treat them — drives all that we do. Dedicated to Patients Making the fight against cancer personal, with immunotherapy created from a patient’s own immune cells Providing immunotherapy treatments that are clinically proven to help extend life, with a generally well tolerated safety profile Offering services and support that improve treatment access Supporting Clinical Practices Partnering with physicians, nurses, and clinicians as they continue to realize the full potential of immunotherapy Helping urologists identify patients who will get the most out of immunotherapy Focused on the Future Expanding access to PROVENGE for more patients, in the United States and around the world Investigating in earlier-stage treatment of prostate cancer with PROVENGE, with the goal of helping even more patients Exploring the use of personalized immunotherapy to treat other cancer types Our History 1992 Inspired by their research at Stanford School of Medicine, Edgar Engleman and Samuel Strober establish Activated Cell Therapy. 1993 Activated Cell Therapy opens its first R&D facility. 1995 The Antigen Delivery Cassette is developed, which will become the basis of the Active Cellular Immunotherapy platform. 1997 Activated Cell Therapy changes its name to Dendreon. 1999 Dendreon moves its headquarters to Seattle, Washington. 2000 Dendreon enters the NASDAQ with an IPO of $45 million to fund trials and preclinical activities for therapeutic cancer vaccines. 2001 Dendreon is awarded a US patent (No. 6,210,662) for the composition of sipuleucel-T. 2003 Phase III IMPACT study evaluating sipuleucel-T in men with advanced prostate cancer begins. Study results eventually serve as the basis for US Food and Drug Administration (FDA) approval. 2006 Dendreon completes Biologics License Application (BLA) submission to the FDA — the first BLA for an active cellular immunotherapy for cancer. 2007 The FDA’s Advisory Committee votes in favor of the safety and efficacy of PROVENGE, advancing sipuleucel-T toward FDA approval. Patients and advocates rally for PROVENGE after the FDA requests additional efficacy data. 2009 Dendreon completes Phase III IMPACT clinical trial and reports positive topline results. 2010 Dendreon receives FDA approval for sipuleucel-T (PROVENGE), the first FDA-approved immunotherapy made from a patient’s own immune cells. Commercial manufacturing of PROVENGE begins in Morris Plains, New Jersey. The New England Journal of Medicine publishes results of the IMPACT trial demonstrating that PROVENGE extends median overall survival for men with advanced prostate cancer by 4.1 months. 2011 The FDA approves PROVENGE manufacturing sites in Seal Beach, California and Union City, Georgia. 2013 More than 10,000 men prescribed PROVENGE. 2014 The National Comprehensive Cancer Network (NCCN) recommends PROVENGE for first-line use in patients with M1 CRPC. 2015 Valeant Pharmaceuticals acquires Dendreon for $495 million. More than 20,000 men prescribed PROVENGE. 2016 Dendreon delivers first profitable year since its inception. 2017 Dendreon resumes operations as a standalone company following acquisition by Sanpower Group for $819.9 million. Dendreon reports its most profitable year in the company’s history. 2018 Over 30,000 men prescribed PROVENGE. 2020 Dendreon celebrates 10th anniversary of the FDA's approval of PROVENGE. Corporate Governance Our patients, their families, and the physicians who treat them are counting on us to conduct business with honesty and integrity. We value our relationship with our employees, partners, contractors, vendors, and the communities in which we operate and hold ourselves to a high ethical standard. Dendreon follows all relevant laws, regulations, guidelines, and codes concerning the pharmaceutical industry. Code of Business Conduct Comprehensive Compliance Program Policy California Declaration of Compliance Our Science Our research led the way in making personalized immunotherapy a reality. Learn More About Us Our Science Partner With Us Newsroom Join Us Contact Us Copyright © 2021 Dendreon Pharmaceuticals LLC. All Rights Reserved. PRV.0310.USA.17 Privacy Policy // Legal Notice // Medical Information // Sitemap IMPORTANT SAFETY INFORMATION INDICATION PROVENGE® (sipuleucel-T) is a prescription medicine that is used to treat certain patients with advanced prostate cancer. PROVENGE is made from your own immune cells. IMPORTANT SAFETY INFORMATION Dendreon uses cookies to analyze traffic, enhance your experience, and provide you with tailored content. By continuing to use this site, you agree with our use of cookies and our Privacy Policy. For more information, visit ourPrivacy Policy. Reject All Accept Cookies